Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Accenture Develops Artificial Intelligence-Powered Solution To Help Improve How Visually Impaired People Live And Work July 27, 2017 Ignyta Reports Granting Of Inducement Awards September 17, 2017 SoCal's Cytori Pink Slips 50% of Workforce in Restructuring September 4, 2017
Accenture Develops Artificial Intelligence-Powered Solution To Help Improve How Visually Impaired People Live And Work July 27, 2017
